(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/209486 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/CN2025/086669

(22) International Filing Date:
01 April 2025 (01.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202410392611.9 02 April 2024 (02.04.2024) CN
202510130727.X 05 February 2025 (05.02.2025) CN

(71) Applicant: **KEYMED BIOSCIENCES (CHENGDU) CO., LTD.** [CN/CN]; Building D2, No. 18, Bio-Town Middle Road, Chengdu Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610219 (CN).

(72) Inventors: **CHEN, Bo**; Building D2, No. 18, Bio-Town Middle Road, Chengdu Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610219 (CN). **WANG, Changyu**; Building D2, No. 18, Bio-Town Middle Road, Chengdu Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610219 (CN). **XU, Gang**; Building D2, No. 18, Bio-Town Middle Road, Chengdu Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610219 (CN). **YAN, Xinyu**; Building D2, No. 18, Bio-Town Middle Road, Chengdu Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610219 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE**; Tower B, 21st Fl. Suite 2108, 38 Xueqing Road, Haidian District, Beijing 100083 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTIBODIES TARGETING IL-13 AND TSLP AND USES THEREOF




FIG. 1A

TSLP/IL-13 BsAb

(57) Abstract: Disclosed herein are antibodies targeting IL-13 and TSLP and uses thereof. Also disclosed are pharmaceutical compositions and conjugates comprising the antibodies and methods of use.

WO 2025/209486 A1